3SBio Inc. (ADR)  

(Public, NASDAQ:SSRX)   Watch this stock  
Find more results for SSRX
16.59
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 10.15 - 16.70
Open     -
Vol / Avg. 0.00/149,084.00
Mkt cap 366.10M
P/E 22.58
Div/yield     -
EPS 0.73
Shares 22.07M
Beta 1.46
Inst. own 52%

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 10.41% 15.31%
Operating margin 7.01% 16.18%
EBITD margin - 19.23%
Return on average assets 4.72% 7.38%
Return on average equity 5.07% 7.87%
Employees 810 -
CDP Score - -

Address

No. 3 A1, Road 10 Shenyang Economy & Technology Development Zone
SHENYANG, LIA 110027
China
+86-24-25811820 (Phone)
+86-24-25811821 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

3SBio Inc. is a biotechnology company in the People's Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.